Stevanato Group S.p.A. (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced that it plans to commence the roadshow for its proposed initial public offering of 40,000,000 ordinary shares.
The initial public offering price is expected to be between 21.00 and 24.00 USD per share. Stevanato Group and Stevanato Holding S.r.l., its significant shareholder, expect to grant the underwriters a 30-day option to purchase up to an additional 6,000,000 ordinary shares of the Company. The Company has applied to list its ordinary shares on the New York Stock Exchange and trade under the ticker symbol “STVN”.
Morgan Stanley, BofA Securities and Jefferies are acting as lead book-running managers for the proposed offering. Citigroup, UBS Investment Bank, KeyBanc Capital Markets, Wells Fargo Securities and William Blair are acting as book runners for the proposed offering. The proposed offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus related to the offering can be obtained from Morgan Stanley & Co. LLC, Prospectus Department, 180 Varick Street, New York, NY 10014, or by email to prospectus@morganstanley.com.
A registration statement on Form F-1 relating to the proposed sale of these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.